The cocrystal advantage: overcoming polymorph patent barriers in generic drug development
Raju G Sharma1, Smitkumar D Vankar1, Mayank G Sharma2
1Department of Chemical Sciences, School of Science, GSFC University, Fertilizer Nagar, Vadodara, Gujarat-391750, India.
Molecular Diversity
|November 10, 2025
Summary
Pharmaceutical cocrystals offer a strategy to overcome patent barriers for generic drugs. This approach creates new, distinct solid forms of active pharmaceutical ingredients (APIs), enabling market entry and improving drug properties.
Area of Science:
- Materials Science
- Pharmaceutical Sciences
- Intellectual Property Law
Background:
- Polymorph patents strategically extend drug exclusivity, hindering generic competition.
- Pharmaceutical cocrystals present a novel approach to circumvent these intellectual property barriers.
Purpose of the Study:
- To review the use of pharmaceutical cocrystals as a strategy for generic drug development.
- To explore the interplay between cocrystal formation, intellectual property law, and regulatory pathways.
Main Methods:
- Review of scientific literature and case studies on pharmaceutical cocrystals.
- Analysis of crystal engineering principles for cocrystal design and synthesis.
- Examination of regulatory frameworks, including the Hatch-Waxman Act and ANDA pathways.
Main Results:
- Cocrystal formation yields new, legally distinct solid forms of APIs, bypassing existing patents.
- Cocrystals can significantly enhance API solubility, dissolution rates, stability, and bioavailability.
- Case studies demonstrate the practical application and commercial viability of cocrystal strategies for APIs like Daprodustat, Roxadustat, and Vadadustat.
Conclusions:
- Pharmaceutical cocrystals offer a non-infringing pathway for generic drug development.
- Cocrystal technology enables the creation of value-added generic products with improved therapeutic performance.
- This strategy facilitates patient access to affordable, enhanced medicines by converging materials science, regulatory law, and drug delivery.
Related Concept Videos
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
141
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
141
01:21Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
649
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
649
01:28Drug Products: Biologics, Biosimilars and Interchangeables
223
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
223
01:17Drug Nomenclature
3.0K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
3.0K
01:18Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
293
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
293
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
170
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
170